Table 2.
Biomarker status in cases that did and did not receive NAT, in biopsy and surgical specimens
| No-NAT group | NAT group | ||||||
|---|---|---|---|---|---|---|---|
| (N = 61) | (N = 78) | ||||||
| Categories | Biopsy | Surgery | p value | Biopsy | Surgery | p value | |
| Estrogen Receptor | Positive | 46 (75.4) | 46 (75.4) | 1 | 66 (84.6) | 64 (82.1) | 0.8299 |
| Negative | 15 (24.6) | 15 (24.6) | 12 (15.4) | 14 (17.9) | |||
| Progesterone Receptor | Positive | 42 (68.9) | 42 (68.9) | 1 | 60 (76.9) | 57 (73.1) | 0.7115 |
| Negative | 19 (31.1) | 19 (31.1) | 18 (23.1) | 21 (26.9) | |||
| HER2 | Positive | 9 (14.8) | 11 (18.0) | 0.4165 | 10 (12.8) | 9 (11.5) | 0.6616 |
| Negative | 47 (77.0) | 41 (67.2) | 60 (76.9) | 59 (75.6) | |||
| Ambiguous | 5 (8.2) | 9 (14.8) | 7 (9.0) | 10 (12.8) | |||
| Ki67 status | Low (< 20%) | 21 (34.4) | 23 (37.7) | 0.5796 | 19 (24.4) | 41 (52.6) | < 0.001 |
| High (≥20%) | 37 (60.7) | 37 (60.7) | 55 (70.5) | 37 (47.4) | |||
| Unknown | 3 (4.9) | 1 (1.6) | 4 (5.1) | 0 (0.0) | |||
NAT Neoadjuvant therapy